If you've started a GLP-1, or you're deciding whether to, one question comes up more than any other in our practice: how long until this works? It helps to look at two timelines at once. There's the GLP-1 medication timeline of scientific progress that brought us here, and there's the personal timeline of what happens week by week once you begin. This post walks through both, with realistic expectations and no hype.

This is general education, not medical advice for your specific situation. TOM Weight Loss is a physician-led telehealth practice serving Texas and Utah, led by Dr. Tran Le, MD, who is triple board-certified in Obesity Medicine, Addiction Medicine, and Occupational & Environmental Medicine.

The GLP-1 medication timeline: from lizard venom to modern obesity care

The story is stranger and longer than most people realize. The class traces back to a discovery in the early 1990s. While investigating bioactive peptides in Gila monster venom, John Eng at the Veterans Affairs Medical Center in New York identified exendin-4, a 39 amino acid peptide that behaved like GLP-1 but resisted enzymatic degradation (the process that breaks it down). That resistance mattered, because your body's own GLP-1 is broken down within minutes.

That finding launched an entire drug class. On April 28, 2005, the FDA's approval of exenatide (Byetta) made it the first GLP-1 receptor agonist approved for clinical use. It was a twice-daily injection, and the proof of concept was clear: you could safely lower blood sugar, and patients tended to lose some weight along the way.

From there, the engineering improved steadily. Later medications were built from the human GLP-1 sequence rather than the lizard peptide, and they were designed to last far longer in the body. A few milestones worth knowing:

2021: Semaglutide 2.4 mg injection (Wegovy) was approved by the US FDA for weight management in June 2021.
2022 to 2023: Tirzepatide was approved for type 2 diabetes (Mounjaro) in May 2022 and for weight management (Zepbound) in November 2023. Tirzepatide is notable because it acts on two receptors. It is the first obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors.
2024: the evidence expanded beyond the scale. The FDA expanded semaglutide's (Wegovy) use to reduce the risk of cardiovascular death, heart attack, or stroke in adults with cardiovascular disease and overweight or obesity, based on a cardiovascular outcomes trial in which it reduced major adverse cardiovascular events by 20% compared with placebo.

The takeaway: these are not brand-new, untested compounds. They're the product of three decades of refinement.

How GLP-1 medications actually work

Understanding the mechanism makes the personal timeline make sense. These medications mimic a gut hormone your body already makes. They mimic the effects of endogenous GLP-1, which is produced in the intestines in response to food intake, and by activating the GLP-1 receptor they enhance glucose-dependent insulin secretion, inhibit glucagon release, and slow gastric emptying.

The weight effect comes from several directions at once. Centrally, GLP-1 receptor agonists modulate brain regions controlling appetite and energy expenditure; peripherally, they improve glycemic control by enhancing insulin secretion, reducing glucagon, delaying gastric emptying, and regulating gut hormones. There's also a hunger-hormone angle: ghrelin, the "hunger hormone" produced by the stomach when it's empty, is decreased by GLP-1 receptor agonists, which contributes to their appetite-suppressing effects. In plain terms: you feel full sooner, stay full longer, and think about food less.

You can read more about the specific options on our medications page, including semaglutide and tirzepatide.

Your personal timeline: what to expect week by week

Here's where patients sometimes get discouraged, so it's worth being honest. GLP-1s are not started at full strength. Dose escalation occurs gradually over several weeks to months to minimize gastrointestinal side effects like nausea while optimizing therapeutic response. A typical schedule increases the dose roughly every four weeks. Package-insert guidance for semaglutide and tirzepatide recommends dose escalation every 4 weeks, with the goal of reaching the maximum recommended dose by about the sixth prescription.

That slow ramp shapes what you'll feel:

Weeks 1 to 4: starting low

This is an adjustment phase. The first 4 to 8 weeks are usually a dose-escalation phase at lower, "starter" doses designed to allow the body to adjust to side effects like nausea. Some people notice reduced appetite early; many don't see much movement on the scale yet, and that's expected. Real-world data show an average weight change of only about 1% by week 8, which may be hard to see day to day for an individual.

Weeks 5 to 16: building up

As the dose steps up, appetite effects usually become more noticeable. The reason the early weeks feel modest is straightforward: the larger trials people read about used full maintenance doses over many months. Trials demonstrating substantial weight loss used full maintenance doses over many months, and people still titrating at lower doses generally lose weight more slowly.

Reaching maintenance

Meaningful results tend to track with reaching, and staying on, your maintenance dose. In our practice, patients often do best when they resist the urge to rush the titration. There's good support for patience here: time to therapeutic effect remains similar at roughly 8 to 12 weeks regardless of escalation speed, so patients don't sacrifice their treatment timeline by following gradual protocols. Pushing the dose up faster mostly buys more side effects, not faster results.

A word on individual variation: the timeline above is a general map, not a promise. Genetics, starting weight, other medications, diet, sleep, and conditions like thyroid disease all influence pace. We adjust the plan to the person. That's the advantage of a physician-led program.

A note on compounded vs. brand-name options

At TOM Weight Loss, our memberships include compounded semaglutide or tirzepatide with the medication included, and we also offer an à la carte plan for brand-name GLP-1s such as Wegovy, Ozempic, Zepbound, and Mounjaro. Compounded medications are not FDA-approved, and we discuss that openly so you can make an informed choice. You can compare the options and costs on our pricing page.

Frequently asked questions

How long does it take for a GLP-1 to start working?

Many people notice appetite changes within the first one to two weeks, but the full effect builds over time. GLP-1 medications typically show initial effects on blood glucose within 1 to 2 weeks and appetite suppression within days to weeks, but reaching full therapeutic response takes longer as doses gradually increase.

Why am I not losing weight in the first month?

Usually because you're still at a starter dose. The early weeks are about helping your body tolerate the medication, not maximizing results, and average changes early on are small and easy to miss. If progress stalls after you reach maintenance, that's worth a conversation with your clinician about dose, diet, and other factors.

Can I speed up my dose to lose weight faster?

Generally no. Faster escalation tends to increase side effects without improving the timeline to therapeutic effect. Steady wins here.

Ready to start?

A GLP-1 works best inside a real clinical relationship, with someone watching your titration, your tolerance, and your goals. If you're in Texas or Utah, you can start a consultation with our physician-led team and get a plan built around your timeline, not a generic one.

GLP-1 Medication Timeline: Progress & What to Expect